Kolibri

Tramadol Hydrochloride/Paracetamol, the active ingredient in Kolibri, is a combination analgesic presented as an oral tablet for oral use. It is indicated for the management of moderate to severe pain in adult patients and is available in the European Union market, formulated to provide rapid onset of analgesia.

GNH USA supplies Kolibri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice and provides regulatory‑compliant documentation for importers.

Kolibri, a combination analgesic, is used to treat pain conditions that involve both nociceptive and neuropathic pathways.

- Moderate to severe pain: provides effective relief when single‑component analgesics are insufficient. - Postoperative pain: helps control pain after surgical procedures. - Acute pain: reduces pain intensity in sudden onset conditions such as injury or dental procedures.

Kolibri may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea - Dizziness - Constipation - Headache - Somnolence - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Seizures - Serotonin syndrome - Severe allergic reactions (anaphylaxis) - Hepatotoxicity - Stevens‑Johnson syndrome

When prescribing Kolibri, clinicians should consider several safety measures.

- Assess renal and hepatic function: adjust use in patients with impairment. - Avoid in patients with known hypersensitivity to tramadol or paracetamol. - Monitor for signs of respiratory depression, especially in opioid‑naïve individuals. - Caution when combined with serotonergic drugs: risk of serotonin syndrome. - Pregnancy and breastfeeding: use only if benefit outweighs risk. - Store at ambient temperature below 25 °C: keep in original container, protect from moisture and light.

Kolibri interacts with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (benzodiazepines, alcohol): additive sedation and respiratory depression. - Serotonergic agents (SSRIs, SNRIs, triptans): potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (fluoxetine, quinidine): increase tramadol plasma levels. - Warfarin: paracetamol may enhance anticoagulant effect. - Diuretics: may reduce analgesic efficacy of tramadol.